After-hours movers: Nautilus gains over strategic review

After-hours movers: Nautilus gains over strategic review

After-hours stock drives:

9 meters Biopharma Inc (NASDAQ:) 42% higher; Today I announce positive final results from a phase II study of furolinated and the results of the end of phase II meeting with the US Food and Drug Administration (FDA). Vurolenatide is a proprietary, long-acting GLP-1 receptor agonist in development for adults with short bowel syndrome (SBS). Based on the meeting results and Phase II data, 9M intends to finalize the Phase 3 protocol in cooperation with the Food and Drug Administration during the fourth quarter. Clinical plans and activities are currently underway to facilitate study initiation upon completion of the protocol. The company plans to provide more details about the phase III clinical development program for Furulinated after completion of the protocol.

Nautilus Group Inc (New York Stock Exchange 🙂 6% higher; announced that its board of directors launched a comprehensive review of strategic alternatives, which may include a potential sale of the company, to identify opportunities to accelerate the company’s digital transformation under Northstar’s previously announced plan and enhance shareholder value.

Corvus Pharmaceuticals, Inc. (NASDAQ 🙂 5% higher; Announced that the IND’s request to start a phase 1/1b clinical trial of mupadolimab (formerly CPI-006) has been approved by the Center for Drug Evaluation of the National Administration of Chinese Medicinal Products. The study will be conducted by Angel Pharmaceuticals Ltd. (Angel Pharma), Corvus partner in China. Mupadolimab is a humanized monoclonal antibody designed to be directed against CD73 with a unique proposed mechanism to activate B cells to generate immune responses to tumor antigens and viruses, in patients with refractory non-small cell lung cancer (NSCLC) and squamous cell head and neck carcinomas. (HNSCC).

READ ALSO :   Review: 'Andor' is, by default, the best Disney+ 'Star Wars' show yet

Execor (NASDAQ:) 5% higher; Announce plans to restructure the company and align resources to continue exploring strategic alternatives that increase shareholder value

Splink (NASDAQ:) 3% higher; It was announced that Jason Child, Splunks’ chief financial officer since 2019, had accepted a position at a leading semiconductor company prior to its initial public offering. Reconfirm the look.

VOXX International Corporation (NASDAQ:) 1% up; President and CEO, Patrick LaVille, bought 13,500 shares on 09/23/22 at $6.8167.

The Latest

To Top